Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Infect Drug Resist. 2012;5:163-73. doi: 10.2147/IDR.S29180. Epub 2012 Nov 29.

Current management options for latent tuberculosis: a review.

Author information

  • 1Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, NC, USA.


Tuberculosis remains the world's second leading infectious cause of death, with nearly one-third of the global population latently infected. Treatment of latent tuberculosis infection is a mainstay of tuberculosis-control efforts in low-to medium-incidence countries. Isoniazid monotherapy has been the standard of care for decades, but its utility is impaired by poor completion rates. However, new, shorter-course regimens using rifamycins improve completion rates and are cost-saving compared with standard isoniazid monotherapy. We review the currently available therapies for latent tuberculosis infection and their toxicities and include a brief economic comparison of the different regimens.


interferon-gamma release assay; isoniazid; rifampin; rifapentine; tuberculin skin test

Free PMC Article
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Dove Medical Press Icon for PubMed Central
    Loading ...
    Write to the Help Desk